Global life sciences giant Bayer has secured the world’s first regulatory approval for its next-generation MRI contrast agent gadoquatrane in Japan, marking a significant shift toward safer, lower-dose imaging.

 

Approved by Japan’s Ministry of Health, Labour, and Welfare under the brand name Ambelvist, the agent is cleared for use across all body regions and the central nervous system in both adults and children—including newborns. 

 

Crucially, it delivers a 60% reduction in gadolinium dose per scan compared to existing options, without compromising image quality—making it the lowest-dose macrocyclic MRI contrast agent currently available in the country.

 

The approval lands amid growing global pressure from regulators and medical societies to minimize patient exposure to gadolinium. 

 

"All medicines should be administered at the lowest effective dose, and MRI contrast agents are no exception,” said Prof. Kohsuke Kudo, Department of Diagnostic Imaging, Hokkaido University, Japan. 

 

“Reducing patients’ lifetime exposure to gadolinium is therefore an important consideration. This is particularly relevant for patients with chronic conditions such as cancer and cardiovascular disease who require repeated MRI examinations, as well as for those with renal impairment and for pediatric patients. By substantially reducing the gadolinium dose while maintaining diagnostic image quality, gadoquatrane may represent a highly valuable option in advancing patient-centered care.”

 

The timing is critical. Japan, home to the highest number of MRI scanners per capita globally, is grappling with an aging population and a rising burden of chronic diseases such as cancer and heart conditions—both of which require frequent imaging.

 

Bayer says the approval is backed by robust clinical evidence, including the pivotal Phase III QUANTI studies and pediatric trials. 

 

“This first approval for Ambelvist is supported by compelling clinical data, underlining its diagnostic value for broad clinical use. The approved comprehensive label in Japan comprises all patient populations and age groups, reducing the need for alternative agents for different patient populations,” said Dr Konstanze Diefenbach, Head of Radiology R&D at Bayer’s Pharmaceuticals Division. 

 

“With this next generation high-relaxivity, low-dose MRI contrast agent demonstrating high stability, Bayer responds to the evolving demand for low-dose options to achieve diagnostic goals. This also showcases our commitment to advancing radiology with innovations that support patients and their treating physicians in getting clear answers about their health.”

 

Bayer is now pushing for global expansion, with regulatory filings underway in the United States, Europe, and China. If cleared, gadoquatrane could set a new benchmark worldwide as the lowest-dose macrocyclic gadolinium-based contrast agent on the market.